Reliance Pharma Fund (G)

Reliance Pharma Fund (G)

Summary Info
Fund Name : Reliance Mutual Fund
Scheme Name : Reliance Pharma Fund (G)
AMC : Reliance Mutual Fund
Type : Open
Category : Equity - Pharma
Launch Date : 10-May-04
Fund Manager : Sailesh Raj Bhan
Net Assets (Rs. cr) : 684.75

NAV Details

NAV Date : 20-May-13
NAV [Rs.] : 72.3
Buy/Resale Price [Rs.] : 71.58
Sell/Repurchase Price [Rs.] : 72.30
Entry Load % : Nil
Exit Load % : NIL

NAV Chart
Graph: 1m |   3m |   6m |   1y |   3y

Performance(%)

* returns above 1 yr. are annualized

  1w 1m 3m 6m 1y 3y 5y Since INC
Scheme Returns 2.8 5.9 9.5 11.5 28.1 13.8 24.5 24.7
Category Avg 2.1 5.7 10.0 13.2 29.1 15.1 20.0 13.4
Category Best 2.9 5.9 10.8 15.4 34.4 19.0 24.5 24.7
Category Worst 1.5 5.3 9.5 11.5 25.8 13.8 14.7 3.8

Latest Payouts

  Dividends Bonus
Ratio NA NA
Date NA NA

Investment Details

Tax Benefits : 112(1) 
Min. Investment(Rs.) : 5,000.00
Increm.Investment(Rs.) : 1.00

In & Out

In
Name of the Company No of shares
No fresh investments made in
Out
Name of the Company No of shares
No investments sold out

Fund Holdings

As on 31-Mar-2013

Asset TypeInstrument NameIndustryNet Assets
(%)		No of SharesMkt Value
(Cr.)
Equity & Equity related Investments
Equitydivi's laboratories ltdPharmaceuticals11.6754,50074.5
Equityranbaxy laboratories ltdPharmaceuticals10.21,500,60065.8
Equitysanofi india ltdPharmaceuticals9.9245,81063.8
Equitycipla ltdPharmaceuticals9.01,523,43957.9
Equitydr. reddy's laboratories ltdPharmaceuticals7.8285,10050.4
Equitysun pharmaceuticals industries ltdPharmaceuticals7.3575,00047.1
Equitysun pharma advanced research company ltdMiscellaneous6.83,858,89144.0
Equityglaxosmithkline pharmaceuticals ltdPharmaceuticals6.0174,70038.5
Equityindoco remedies ltdPharmaceuticals5.15,607,27832.6
Equityipca laboratories ltdPharmaceuticals4.9600,31931.8
Equityabbott india ltdPharmaceuticals4.5218,00029.2
Equityzydus wellness ltdFMCG3.7560,64524.0
Equitycadila healthcare ltdPharmaceuticals3.5300,35122.3
Equitybiocon ltdPharmaceuticals3.2750,00020.5
Equityglenmark pharmaceuticals ltdPharmaceuticals1.8250,00011.6
Equityfulford india ltdPharmaceuticals1.2110,9017.9
Equitymerck ltdPharmaceuticals1.096,6966.1
Equitylupin ltdPharmaceuticals0.990,0005.7
Equityunichem laboratories ltdPharmaceuticals0.8289,5745.0
Equityvimta labs ltdMiscellaneous0.1310,3130.5
Debt Investments
NCDdr. reddy's laboratories ltdAA+0.0318,6000.2
Cash & Cash Equivalent
CBLOcbloUR / N.A.1.0NA6.3
Net CA & Othersnet current assets-/-[0.2]NA[1.0]

My Watchlist

Key Information

Fund House: Reliance Mutual Fund
Incorporation Date : 24-Feb-1995
Total Assets Managed (Cr.) : 26,420.11
Trustee/s : S Santhanakrishnan
Chairman : N/A
CEO / MD : Mr. Sundeep Sikka
CIO : N/A
President : N/A
Director/s : Sushil C. Tripathi
Compliance Officer/s : Mr. Muneesh Sud
Investor Service Officer/s : Mr. Bhalchandra Joshi
Fund Manager/s : Sailesh Raj Bhan

Other Information

Auditors :  N/A
Registered Office : 11th & 12th floor, One Indiabulls ,Centre, Tower 1, 841, Senapati ,Bapat Marg,Elphinstone Road,Mumbai-13
Contact Nos : 022 - 3099 4600
Fax : 022 - 3099 4699
Email : customer_care@reliancemutual.com
Website :  www.reliancemutual.com

Fund Manager Speak

Tushar Pradhan, CIO, HSBC Mutual Fund
“Our research shows that a disciplined approach to buying companies that look attractive on this matrix provides significant longer term outperformance.”..
Vikaas Sachdeva, CEO, Edelweiss Asset Management Ltd
Kaushik Dani, Head of Equity, Peerless Funds Management Company
View all Fund Manager Speak >>

IIFL Blogs

R. Venkataraman
Wish it is a Happy New Year
We live in neither the best of times, nor the worst of times. All indications, at least on the macroeconomic front point towards a year, which may not be happy after all. For that matter, even 2010...
Billy Wang
PetroChina’s new guideline on public communica...
Recently a leaked internal directive from PetroChina is making wild runs on the Chinese Internet – it is a guideline on what not to say in the oil major’s press releases and financial reporting.